Dasatinib instructions, indications, usage and dosage, side effects

Dasatinib is a drug used to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) that is resistant or intolerant to imatinib mesylate. This drug is a protein kinase inhibitor that inhibits the proliferation and survival of leukemia cells by inhibiting BCR-ABL tyrosine kinase activity and blocking the BCR-ABL signaling pathway. Dasatinib is not only suitable for patients in the chronic phase of chronic myelogenous leukemia, but also for patients in the accelerated phase and blast phase, providing a new treatment option for patients who are ineffective or intolerant to imatinib mesylate treatment.

In terms of indications, dasatinib is mainly used to treat patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase, accelerated phase and blast phase, as well as patients with Ph+ acute lymphoblastic leukemia (ALL). These patients typically have received treatment regimens including imatinib mesylate but require a change of regimen due to resistance or intolerance. Dasatinib can effectively control the progression of these diseases by inhibiting multiple kinases such as BCR-ABL kinase and SRC family kinases.

In terms of usage and dosage, the dosage of dasatinib is determined based on the patient’s disease stage and tolerance. For patients with Ph+ chronic phase CML, the recommended starting dose is 100 mg once daily, and the taking time should be consistent, either in the morning or evening. If patients fail to achieve hematological or cytogenetic remission at the recommended starting dose, the dose may be increased to 140 mg once daily. For patients with Ph+ accelerated phase, blast phase CML, and patients with Ph+ acute lymphoblastic leukemia, the recommended starting dose is 70 mg twice daily, taken orally in the morning and evening. If the patient tolerates it well but does not respond well, the dose can be increased to 100 mg twice daily. Dasatinib tablets should be swallowed whole, without crushing or cutting, and can be taken with food or on an empty stomach.

In terms of side effects, the use of dasatinib may cause a series of adverse reactions. These reactions may include bone marrow suppression (such as anemia, leukopenia, and thrombocytopenia), gastrointestinal symptoms (such as nausea, vomiting, diarrhea), fluid retention (such as pleural effusion, edema), allergic reactions (such as rash, skin itching), abnormal bleeding, liver function damage, etc. In addition, serious adverse reactions such as low phosphate levels, toxic epidermal necrolysis, and tumor lysis syndrome may occur. Therefore, during the use of dasatinib, patients need to closely monitor blood, liver and kidney function and other indicators, and pay attention to observe the body's reaction. Once any symptoms of discomfort occur, you should seek medical treatment promptly.

Overall, dasatinib, as an effective anti-tumor drug, has demonstrated significant efficacy and potential in the treatment of chronic myelogenous leukemia and other types of leukemia. However, its use also needs to be carried out under the guidance of a doctor to ensure safe and effective disease control. During the use of dasatinib, patients should strictly abide by medical instructions, take medications on time, and closely monitor body reactions. At the same time, patients should also pay attention to maintaining good living habits and mentality to improve treatment effects and quality of life.